Fountain Life

Aggressive early detection using advanced imaging and liquid biopsies.

Founded by Peter Diamandis, Tony Robbins, and Dr. Bill Kapp, Fountain Life focuses heavily on what they term "interception"—identifying asymptomatic diseases in their earliest stages.

The Apex Protocol ($19,500/year)

The core offering is the Apex membership. The value proposition rests entirely on their diagnostic stack:

• Whole-Body MRI: Using AI-enhanced interpretation to find tumors as small as 1.5cm.
• Cleerly CCTA: AI analysis of coronary CT angiography to quantify non-calcified, soft plaque (the primary driver of acute myocardial infarction).
• Grail Galleri MCED: Multi-cancer early detection blood test targeting 50+ cancers via cell-free DNA methylation patterns.
• DEXA Scan: For precise bone density and visceral fat quantification.
• WGS & Biomarkers: Whole genome sequencing alongside a 100+ biomarker blood panel.

Analysis & Critique

Fountain Life offers the most robust standard diagnostic package available commercially. Their reliance on the Cleerly scan for cardiovascular risk is specifically commendable, as it moves past the outdated standard of LDL-C and even ApoB alone, looking directly at disease burden.

The Catch: The cost is prohibitive, and false positives from the Grail Galleri test or incidentalomas on the WB-MRI can lead to unnecessary, invasive follow-up procedures. Their therapeutic pipeline (stem cells, exosomes) is also less rigorously validated than their diagnostic pipeline.

FAQ